Epitalon: what the research says.
Last updated May 22, 2026
A synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed in St. Petersburg by Vladimir Khavinson and colleagues, studied primarily in Russian and Eastern European gerontology literature for pineal function, melatonin rhythm, and telomerase activity. Here’s what the evidence supports, and where the boundaries are.
Regulatory notice: Epitalon is currently classified as an FDA Category 2 bulk drug substance. As of April 2026, licensed compounding pharmacies are not legally permitted to prepare or dispense it. Epitalon is not offered by PepScribe. This page is for educational purposes only and does not constitute medical advice or an offer to sell any product.
On February 27, 2026, the U.S. Department of Health and Human Services announced an intent to reclassify certain peptides, potentially including Epitalon. This announcement has not been formally published in the Federal Register and carries no legal effect until it is. Do not interpret this page as confirmation that Epitalon’s legal status has changed or that PepScribe will offer it in the future.
What Epitalon is.
Epitalon is a synthetic 4-amino-acid peptide with the sequence Ala-Glu-Asp-Gly (alanine, glutamic acid, aspartic acid, glycine). It was designed as a synthetic analog of Epithalamin, a polypeptide complex isolated from the pineal gland of cattle. Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology developed the tetrapeptide in the 1980s and 1990s as part of a broader research program on short peptides derived from animal tissue extracts.
The Khavinson group’s working hypothesis is that very short peptides can act as tissue-specific bioregulators, binding to DNA and modulating gene expression in the tissues they were originally derived from. For Epitalon, that target tissue is the pineal gland, the structure that produces melatonin and helps coordinate circadian and seasonal rhythms. The bulk of the published research on Epitalon comes out of this single research program and its collaborators, and most of it sits in Russian-language journals or in English-language journals with limited Western replication.
How it works (proposed mechanisms).
Telomere length and telomerase induction
Khavinson et al. (2003, Bulletin of Experimental Biology and Medicine) reported that Epitalon induced telomerase activity and elongated telomeres in cultured human somatic cells. Telomeres are the protective DNA sequences at the ends of chromosomes that shorten with each cell division. The telomerase hypothesis is the most cited mechanism in the marketing literature around Epitalon, but it rests primarily on this in-vitro work and has not been reproduced in large independent studies.
Melatonin rhythm and circadian effects
Anisimov, Khavinson, and colleagues have published a series of preclinical studies (1998 onward) suggesting that Epitalon restores age-related declines in nocturnal melatonin secretion in rats and primates. The proposed mechanism is direct modulation of pineal cell activity, which is consistent with its Epithalamin parent compound. This pineal connection is the original rationale for the molecule.
Short-peptide DNA binding hypothesis
Khavinson and colleagues have proposed that short peptides such as Epitalon bind directly to specific promoter regions in DNA and influence transcription. Published work in Neuroendocrinology Letters (Khavinson, 2002) and related journals describes effects on cell-cycle genes, antioxidant enzymes, and apoptosis pathways in cultured cells. The direct DNA-binding mechanism is contested in mainstream molecular biology and remains an open question.
Oxidative stress markers
Animal studies from the Khavinson and Anisimov groups have reported reduced markers of oxidative damage and increased activity of endogenous antioxidant systems following Epitalon administration. These effects are often described as downstream of melatonin restoration, since melatonin itself is a potent endogenous antioxidant. As with the other mechanisms, the data come predominantly from a single research lineage.
Most of the mechanistic and clinical work on Epitalon comes from one Russian research program (Khavinson, Anisimov, and collaborators). Independent Western replication is limited, and large modern randomized controlled trials have not been published.
What the research suggests.
The Khavinson and Anisimov groups have published extensively in gerontology-focused journals over several decades. The work covers cell culture, animal lifespan studies, and small clinical cohorts, mostly in elderly Russian patients. Western peer-reviewed validation is sparse.
Animal lifespan studies
Anisimov et al. (2003, Mechanisms of Ageing and Development) reported increased mean lifespan in mice receiving Epitalon, along with reduced incidence of spontaneous tumors in some cohorts. Earlier work by Anisimov and Khavinson in Russian-language journals had reported similar patterns in rats. Lifespan-extension claims based on rodent studies do not reliably translate to humans, and these studies have not been replicated by independent Western labs at scale.
Telomere length in human cells
Khavinson et al. (1999, 2003) reported telomerase induction and telomere elongation in cultured human somatic cells exposed to Epitalon. This is the foundational result behind the longevity framing. It is in-vitro work, it has not been reproduced widely outside the original group, and any inference from cell-culture telomere effects to human aging is speculative.
Melatonin and sleep architecture
Korkushko, Khavinson, and colleagues have published small clinical reports in elderly Russian patients suggesting restored nocturnal melatonin secretion patterns and modest improvements in sleep parameters following Epitalon administration. These cohorts are small, short, and not blinded to modern RCT standards.
Retinal and ophthalmic research
A subset of Khavinson’s work has explored short peptides in retinitis pigmentosa and other retinal degenerative conditions, with Epitalon and related peptides reported to slow functional decline in small open-label series. This research is interesting but narrow, and independent replication in international ophthalmology journals is limited.
Administration (research context).
In the Russian and Eastern European clinical literature, Epitalon has been studied primarily as a subcutaneous or intramuscular injection in short cycles (typically 10 to 20 days), repeated at intervals over months or years. The parent compound, Epithalamin, has been used in Russian gerontology clinics for decades in similar cyclical protocols.
There is no internationally standardized dosing for Epitalon. The protocols in the published Russian work vary by indication, patient age, and study, and have not been validated through US or European regulatory pathways.
This is research context, not prescribing guidance. PepScribe does not currently offer Epitalon and this information should not be interpreted as a dosing recommendation.
Side effects & safety considerations.
Based on the available data from Russian and Eastern European clinical use and published research.
Reported side effects
- Injection site reactions (redness, mild swelling, transient soreness)
- Drowsiness or shifts in sleep timing (consistent with melatonin pathway effects)
- Mild headache, typically transient
Safety profile notes
The Russian preclinical and clinical literature reports a generally favorable short-term safety profile, including in elderly cohorts. Long-term safety in modern, internationally regulated populations has not been established. The molecule has not undergone the toxicology, mutagenicity, and carcinogenicity testing required for FDA approval. People considering any peptide associated with telomerase or cell-cycle modulation should be aware that the long-term implications of those pathways in humans are not fully understood.
Consult a healthcare provider before considering any peptide therapy. This information is educational and does not replace medical advice. Individual results may vary.
Legal status.
Epitalon is not FDA-approved as a drug in the United States. It sits on the FDA’s Category 2 bulk substance list, which is the transitional tier for 503A compounding. Licensed compounding pharmacies cannot legally prepare or dispense it under standard rules as of April 2026.
In Russia, the parent compound Epithalamin has a long history of clinical use, and Epitalon has been studied within that same gerontology research tradition. Neither has FDA drug approval, and Epitalon’s Category 2 classification means it cannot be used as a bulk ingredient in US compounding.
A broader HHS peptide review announced February 27, 2026 may revisit the Category 2 list, but no final regulatory action has been published for Epitalon. Products labeled as Epitalon on the gray market are unregulated research chemicals without pharmaceutical-grade quality assurance, identity testing, or sterility controls.
NAD+
Supports cellular energy production, sirtuin activity, and DNA repair pathways that intersect with the same longevity biology Epitalon research targets. Physician-prescribed and delivered.
Get startedSermorelin
Growth hormone-releasing peptide that supports deep sleep, recovery, and the endocrine rhythms that decline with age. A clinically established option, physician-prescribed.
Get startedDeep dives
More on Epitalon.
Research-backed articles covering specific topics in depth.
Explore clinician-led alternatives.
Epitalon is not available through US compounding. PepScribe's programs and Tier 1 peptides route you to legal, evidence-supported options under clinician supervision.